We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optional Sub-study to Intraoperative Imaging With ICG Registry

This study is currently recruiting participants.
Verified July 2016 by Abramson Cancer Center of the University of Pennsylvania
Sponsor:
ClinicalTrials.gov Identifier:
NCT02651246
First Posted: January 8, 2016
Last Update Posted: July 20, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania
January 6, 2016
January 8, 2016
July 20, 2016
December 2015
December 2021   (Final data collection date for primary outcome measure)
Number of tumor recurrence [ Time Frame: 10 years ]
Same as current
Complete list of historical versions of study NCT02651246 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Optional Sub-study to Intraoperative Imaging With ICG Registry
Optional Sub-study to Intraoperative Imaging With ICG Registry
The primary goal of this optional sub-study is to record what tissues fluoresce in the operating room, and then to identify if these lesions are cancer when the histopathology is performed.
Not Provided
Observational [Patient Registry]
Observational Model: Cohort
Time Perspective: Prospective
10 Years
Not Provided
Probability Sample
cancer patients who undergo surgery and intraoperative imaging
  • Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer
  • Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer
  • Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
Other: data collection
Not Provided
Not Provided
 
Recruiting
500
Not Provided
December 2021   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients >= 18 years of age
  • Patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and are at risk for recurrence.
  • Good operative candidate as determined by the treating physician and/or multidisciplinary team
  • Subject capable of giving informed consent and participating in the process of consent.

Exclusion Criteria:

  • Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery
  • Vulnerable patient populations
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Sunil Singhal, MD, Ph.D 855-216-0098 PennCancerTrials@emergingmed.com
United States
 
 
NCT02651246
UPCC 31915
Yes
Not Provided
Not Provided
Abramson Cancer Center of the University of Pennsylvania
Abramson Cancer Center of the University of Pennsylvania
Not Provided
Principal Investigator: Sunil Singhal, MD, Ph.D Abramson Cancer Center of the University of Pennsylvania
Abramson Cancer Center of the University of Pennsylvania
July 2016